首頁
Protagonist Therapeutics, Inc.

3月 2026Protagonist Therapeutics...的市場佔有率分析

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.

健康 > 生物技術和製藥

域名protagonist-inc.com

成立年份2007

僱員51 - 200

年度營收$200M - $500M

Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.（包含公司地區）

protagonist-inc.com

查看更多網站流量與參與度資訊

Protagonist Therapeutics, Inc.截至 3月 2026 的總收入為 200M - 500M

Protagonist Therapeutics, Inc. 熱門網域產生的總收入

Protagonist Therapeutics, Inc. 熱門網域 3 年內的總收入

Protagonist Therapeutics, Inc. 熱門網域的總收入

protagonist-inc.com200M - 500M

透過銷售情報查看更多內容

Protagonist Therapeutics, Inc.的熱門網域總造訪量

了解Protagonist Therapeutics, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

protagonist-inc.com9K

透過銷售情報查看更多內容

Protagonist Therapeutics, Inc.的熱門網域平均造訪時長

分析Protagonist Therapeutics, Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

protagonist-inc.com00:00:15

透過銷售情報查看更多內容

Protagonist Therapeutics, Inc.的熱門網域平均頁面瀏覽量

了解Protagonist Therapeutics, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

protagonist-inc.com2.36

透過銷售情報查看更多內容

Protagonist Therapeutics, Inc.按網域劃分的熱門競爭對手

3月 2026的熱門類似網站，依相似度排名

annexonbio.com公司名Annexon Biosciences僱員51 - 200總部美國, 加利福尼亞, Brisbane年度營收$15M - $25M訪問總量5.2K健康 > 生物技術和製藥

使用的熱門技術Protagonist Therapeutics, Inc.

这些是Protagonist Therapeutics, Inc.顶级域名使用的行业网站技术

轉換與分析 (3)

Google Analytics

行動裝置 (3)

Meta Viewport

付費廣告 (2)

Google Adsense

內容管理系統 (2)

WordPress

更多技術

8

檢視所有

新聞與訊號來自Protagonist Therapeutics, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Protagonist Therapeutics received financing of $300M on Jan 1st '24.Under the parties' January 2024 collaboration agreement, Protagonist received a $300 million upfront payment and retained the right to elect either a 50:50 U.S. profit and loss share or an opt-out structure featuring enhanced payments, milestones, and worldwide royalties.

新聞AbbVie identified as competitor of Protagonist Therapeutics.AbbVie is ready to face off against the newest kid on the immunology block: Johnson & Johnson and Protagonist Therapeutics' peptide pill Icotyde.

新聞Protagonist Therapeutics attends event 67th Annual American Society of Hematology (ASH) Annual Meeting.NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass. - Protagonist Therapeutics, Inc. ("Protagonist") ( NASDAQ:PTGX) and Takeda ( TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.